Reference
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants Internet Document : 17 Jan 2023. Available from: URL: https://recalls-rappels.canada.ca/en/alert-recall/evusheld-tixagevimab-and-cilgavimab-injection-risk-prophylaxis-or-treatment-failure-0
Rights and permissions
About this article
Cite this article
Cilgavimab/tixagevimab unlikely to be active against some COVID-19 Omicron subvariants. Reactions Weekly 1941, 1 (2023). https://doi.org/10.1007/s40278-023-32264-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-32264-x